Nevro Corp. 1,625,000 Shares of Common Stock Underwriting AgreementNevro Corp • April 7th, 2020 • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 1,625,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 243,750 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. Any reference herein to the Underwriters shall be deemed to refer to a single Underwriter if only a single Underwriter is named in Schedule I hereto.
April 1, 2020Nevro Corp • April 7th, 2020 • Surgical & medical instruments & apparatus • England
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Morgan Stanley & Co. International plc (“Dealer”) and Nevro Corp. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
NEVRO CORP. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 1st, 2015 • Nevro Corp • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.001 per share, of the Company, and certain stockholders of the Company named in Schedule 2 hereto (the “Selling Stockholders”) propose to sell to the several Underwriters an aggregate of [•] shares of common stock of the Company (collectively, the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
From: Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036 Attn: ###, Managing Director, Associate General Counsel Telephone: ### Facsimile: ### June 7, 2016 To: Nevro Corp. Redwood City, CA...Letter Agreement • June 13th, 2016 • Nevro Corp • Surgical & medical instruments & apparatus • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Nevro Corp. (“Company”) to Bank of America, N.A. (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Company and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
April 1, 2020Nevro Corp • April 7th, 2020 • Surgical & medical instruments & apparatus • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Nevro Corp. (“Company”) to Morgan Stanley & Co. International plc (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Company and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
NEVRO CORP. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 10th, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of [·] by and between Nevro Corp., a Delaware corporation (the “Company”), and «Indemnitee» (“Indemnitee”).
NEVRO CORP. CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • August 1st, 2023 • Nevro Corp • Surgical & medical instruments & apparatus • California
This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Greg Siller (“Executive”) and Nevro Corp. (the “Company”). This Agreement is effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
NEVRO CORP. AND WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 13, 2016 to Indenture dated as of June 13, 2016 1.75% Convertible Senior Notes due 2021First Supplemental Indenture • June 13th, 2016 • Nevro Corp • Surgical & medical instruments & apparatus • New York
FIRST SUPPLEMENTAL INDENTURE dated as of June 13, 2016 (this “Supplemental Indenture”) between Nevro Corp., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01), and Wilmington Trust, National Association, a national banking association organized under the laws of the United States of America, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture dated as of June 13, 2016 between the Company and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 1st, 2023 • Nevro Corp • Surgical & medical instruments & apparatus • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 30, 2023, by and among Nevro Corp., a Delaware corporation (the “Company”), and Braidwell Transaction Holdings LLC – Series 4, a Delaware limited liability company (“Braidwell”).
June 8, 2016Nevro Corp • June 13th, 2016 • Surgical & medical instruments & apparatus • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Nevro Corp. (“Company”) to Morgan Stanley & Co. International plc (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Company and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
Nevro Corp. Underwriting AgreementNevro Corp • April 7th, 2020 • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $165,000,000 principal amount of its 2.75% Convertible Senior Notes due 2025 (the “Underwritten Securities”) and, at the option of the Underwriters solely to cover over-allotments, up to an additional $24,750,000 principal amount of its 2.75% Convertible Senior Notes due 2025 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such Option Securities granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock at the Company’s
ContractNevro Corp • December 1st, 2023 • Surgical & medical instruments & apparatus • New York
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, INCLUDING PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER SECTION 4(a)(7) OF THE SECURITIES ACT OR APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION OR GUIDANCE, SUCH AS A SO-CALLED “4[a](1) AND A HALF SALE.” NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
Nevro Corp.Nevro Corp • June 13th, 2016 • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $150,000,000 principal amount of its 1.75% Convertible Senior Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriters solely to cover over-allotments, up to an additional $22,500,000 principal amount of its 1.75% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such Option Securities granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock at the Company’
MULTI-TENANT SPACE LEASE (“NNN”)Acceptance Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • California
THIS MULTI-TENANT SPACE LEASE (the “Lease”), dated as of March 15, 2010, (the “Reference Date”) is made and entered into by and between DEERFIELD CAMPBELL LLC, a California limited liability company (“Landlord”), and NEVRO CORPORATION, a Delaware corporation (“Tenant”), with reference to those matters set forth hereinafter.
GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000Nevro Corp • April 7th, 2020 • Surgical & medical instruments & apparatus • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Nevro Corp. (“Company”) to Goldman Sachs & Co. LLC (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Company and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
NEVRO CORP. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 1st, 2023 • Nevro Corp • Surgical & medical instruments & apparatus • California
This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into by and between D. Keith Grossman (“Executive”) and Nevro Corp. (the “Company” and, together with Executive, the “Parties”), effective as of April 24, 2023 (the “Effective Date”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • October 15th, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Minnesota
This Amended and Restated License Agreement (the “Agreement”) is by and among Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (“MAYO”), Venturi Group, LLC, located at 2800 Patton Road, St. Paul, Minnesota 55113 (“VGL,” and, together with MAYO, the “FOUNDERS”), and NBI Development, Inc., a private for-profit company, located at 2800 Patton Road, St. Paul, Minnesota 55113 (“COMPANY”).
NEVRO CORPORATION INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus
THIS AGREEMENT, made as of this «Day» day of «Month», «Year» (the “Grant Date”), by and between Nevro Corporation, a Delaware corporation (the “Company”) and «Optionee» (“Optionee”).
FIRST AMENDMENT TO LEASELease • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus
This First Amendment to Lease (“First Amendment”) is entered into as of October 18, 2012 (“Reference Date”), by and between Deerfield Campbell LLC, a California limited liability company (hereinafter called “Landlord”), and Nevro Corporation, a Delaware corporation (hereinafter called “Tenant”), with reference to the following facts:
NEVRO CORP. AMENDMENT TO AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • California
This Amendment to Amended and Restated Registration Rights Agreement (this “Amendment”), by and among Nevro Corp., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company is made and entered into as of March 5, 2013, with respect to that certain Amended and Restated Registration Rights Agreement, dated as of February 8, 2013, by and among the Company and each of the stockholders of the Company listed on Exhibit A thereto, as such Exhibit A may be amended from time to time (the “Stockholders”) (the “Original Agreement”). Capitalized terms used in this Amendment and not otherwise defined shall have the meaning ascribed to them in the Original Agreement.
COOPERATION AGREEMENTCooperation Agreement • February 21st, 2024 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of February 20, 2024, by and among Nevro Corp., a Delaware corporation (the “Company”) and the persons set forth on Exhibit A hereto (collectively, the “Engaged Group” and, for clarity, as applicable, including each member thereof acting individually). The Company and the Engaged Group are each herein referred to as a “Party” and collectively, the “Parties.” Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in Section 12 below.
NEVRO CORP. EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2016 • Nevro Corp • Surgical & medical instruments & apparatus • California
This Employment Agreement (the “Agreement”) is made and entered into by and between Rami Elghandour (“Executive”) and Nevro Corp. (the “Company”) (together referred to herein as the “Parties”), effective as of June 1, 2016 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 9, 2012 (the “Prior Agreement”) and any other agreement to which the Company is a party with respect to Executive’s employment with the Company, including without limitation that certain Change in Control Severance Agreement between Executive and the Company dated as of December 4, 2014 (the “Change in Control Agreement”), except for the Proprietary Information and Inventions Agreement executed by Executive (the “Confidential Information Agreement”).
March 8, 2011 Re: Offer Letter Dear Michael:Nevro Corp • October 3rd, 2014 • Surgical & medical instruments & apparatus • California
On behalf of Nevro Corp. (the “Company”), I am pleased to offer you employment with the Company on the terms set forth in this letter (this “Agreement”). We have enjoyed our interactions with you and believe that you will provide the Company with the type of leadership that it needs at this time. We believe the Company represents an extraordinary opportunity for you as well.
SUPPLY AGREEMENT BETWEEN CENTRO DE CONSTRUCCION DE CARDIOESTIMULADORES DEL URUGUAY S.A. AND NEVRO CORP. March 13, 2015Supply Agreement • May 29th, 2015 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This supply agreement (“Agreement”) is entered into on March 13, 2015 (the “Effective Date”) by and between Centro de Construccion de Cardioestimuladores del Uruguay S.A. (“CCC”), an Uruguay corporation with its principal place of business at General Paz 1371, Montevideo, Uruguay, CP 11400 and Nevro Corp. (“Nevro”), a Delaware corporation with its principal place of business at 4040 Campbell Avenue, Suite 210, Menlo Park, CA 94025. CCC and Nevro are referred to collectively as the “Parties”, individually as a “Party.”
SUPPLY AGREEMENTSupply Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This SUPPLY AGREEMENT (“Agreement”) is made as of this 23rd day of July, 2014 (the “Effective Date”), by and between Pro-Tech Design and Manufacturing, Inc., a California S corporation, having its principal place of business at 14561 Marquardt Ave., Santa Fe Springs, CA 90670 (“Pro-Tech”) and Nevro Corporation, a Delaware corporation, having its principal place of business at 4040 Campbell Avenue, Suite 210, Menlo Park, CA 94025 (“Nevro”).
AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (this “Agreement”), dated as of February 8, 2013, is by and among Nevro Corp., a Delaware corporation (the “Corporation”), those certain holders of Common Stock of the Corporation and holders of options to acquire shares of Common Stock of the Corporation listed on Schedule 1 hereto (together with any other Person who hereafter becomes party hereto pursuant to Section 11 hereof, each, individually, a “Significant Common Stockholder” and, collectively, the “Significant Common Stockholders”), and each holder of the Corporation’s Preferred Stock (as such term is defined below) listed on Schedule 1 hereto (together with any other Person who hereafter becomes party hereto pursuant to Section 11 hereof, each, individually, an “Investor” and, collectively, the “Investors” and together collectively with the Significant Common Stockholders, the “Stockholders”). A list of the name, address and shares of each class of capital stock of the Corporat
NEVRO CORP. AMENDMENT TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENTStockholders’ Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This Amendment to Amended and Restated Stockholders’ Agreement (this “Amendment”), by and among Nevro Corp., a Delaware corporation (the “Corporation”), and the undersigned stockholders of the Corporation is made and entered into as of March 5, 2013, with respect to that certain Amended and Restated Stockholders’ Agreement, dated as of February 8, 2013, by and among the Corporation and those certain holders of Common Stock of the Corporation and holders of options to acquire shares of Common Stock of the Corporation listed on Schedule 1 thereto (together with any other Person who thereafter becomes party thereto pursuant to Section 11 thereof, each, individually, a “Significant Common Stockholder” and, collectively, the “Significant Common Stockholders”), and each holder of the Corporation’s Preferred Stock (as such term is defined therein) listed on Schedule 1 thereto (together with any other Person who thereafter becomes party thereto pursuant to Section 11 thereof, each, individuall
NEVRO CORPORATION NON-INCENTIVE STOCK OPTION AGREEMENTNon-Incentive Stock Option Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus
THIS AGREEMENT, made as of this «Day» day of «Month», «Year» (the “Grant Date”) by and between Nevro Corporation, a Delaware corporation (the “Company”) and «Optionee» (“Optionee”).
NEVRO CORPORATION STOCK PURCHASE RIGHT GRANT NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT2007 Stock Incentive Plan • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • California
Pursuant to its 2007 Stock Incentive Plan (the “Plan”), Nevro Corporation, a Delaware corporation (the “Company”), hereby grants to the Purchaser listed below (“Purchaser”), the right to purchase the number of shares of the Company’s Common Stock set forth below (the “Shares”) at the purchase price set forth below (the “Stock Purchase Right”). This Stock Purchase Right is subject to all of the terms and conditions set forth herein, in the Plan and in the certain Restricted Stock Purchase Agreement attached hereto as Exhibit A (the “Restricted Stock Purchase Agreement”), each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Stock Purchase Right Grant Notice (the “Grant Notice”) and the Restricted Stock Purchase Agreement.
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • California
THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 8, 2013, is made and entered into by and among Nevro Corp., a Delaware corporation (the “Company”), and each of the stockholders of the Company listed on Exhibit A hereto, as such Exhibit A may be amended from time to time (the “Stockholders”). For the purposes of this Agreement, the term “Company” shall be deemed to include and refer to any successor in interest to the Company, whether by means of statutory conversion, merger, consolidation, recapitalization, reorganization or otherwise.
NEVRO CORP. AND WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of April 6, 2020 to Indenture dated as of June 13, 2016 2.75% Convertible Senior Notes due 2025Second Supplemental Indenture • April 7th, 2020 • Nevro Corp • Surgical & medical instruments & apparatus • New York
SECOND SUPPLEMENTAL INDENTURE dated as of April 6, 2020 (this “Supplemental Indenture”) between Nevro Corp., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01), and Wilmington Trust, National Association, a national banking association organized under the laws of the United States of America, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture dated as of June 13, 2016 between the Company and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus
This Amendment to Supply Agreement (“Amendment”) is entered into as of March 20, 2013 (“Amendment Effective Date”) by and between C.C.C. Del Uruguay S.A. (“CCC”), an Uruguay corporation with its principal place of business at General Paz 1371, Montevideo, Uruguay, CP 11400, and Nevro Corp. (“Nevro”), a Delaware corporation with its principal place of business at 4040 Campbell Avenue, Suite 210, Menlo Park, CA 94025. CCC and Nevro are referred to collectively as the “Parties”, individually as a “Party”.
STELLAR MANUFACTURING AGREEMENTStellar Manufacturing Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Minnesota
This Stellar Manufacturing Agreement (“Agreement”), effective the 1st day of July, 2009 (the “Effective Date”), by and between Stellar Technologies, Inc., a Minnesota corporation (“Stellar”) and Nevro Corp., a Delaware corporation, having a place of business at 411 Acacia Avenue, Palo Alto, CA 94306 (“Customer”) (Stellar and Customer are the “Party[ies]”).
SUPPLY AGREEMENT BETWEEN AND NEVRO CORP April 1, 2012Supply Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • New York
This supply agreement (“Agreement”) is entered into on April 1, 2012 (the “Effective Date”) by and between C.C.C. Del Uruguay S.A. (“CCC”), an Uruguay corporation with its principal place of business at General Paz 1371, Montevideo, Uruguay, CP 11400 and Nevro Corp (“Nevro”), a California corporation with its principal place of business at 4040 Campbell Avenue, Suite 210, Menlo Park, CA 94025. CCC and Nevro are referred to collectively as the “Parties”, individually as a “Party”.
PRODUCT SUPPLY AND DEVELOPMENT AGREEMENTDevelopment and Supply Agreement • October 3rd, 2014 • Nevro Corp • Surgical & medical instruments & apparatus • Delaware
This PRODUCT SUPPLY AND DEVELOPMENT AGREEMENT (“Agreement”), effective as of April 15, 2009 (the “Effective Date”), is by and between EaglePicher Medical Power LLC (“EPMP LLC”), a Delaware Corporation having an address of “C” and Porter Streets, Joplin, MO 64801 and Nevro Corporation (“Buyer”), a Delaware Corporation, having its principal place of business at 411 Acacia Avenue, Palo Alto, CA 94306.
